Cullinan Management Inc (CGEM) Stock Price

8.52 ▲ +0.24 (+2.90%)
Open: 8.28 Vol: 457.13K Day's range: 8.07 - 8.59 May 01, 16:00 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
CGEM Technical Analysis
5 mins 30 mins Hourly Daily Weekly
BUY BUY BUY BUY SELL
  5 mins 30 mins Hourly Daily Weekly
MA5 8.54▼ 8.50▲ 8.47▲ 8.12▲ 7.93▲
MA10 8.53▼ 8.43▲ 8.36▲ 8.15▲ 8.22▲
MA20 8.51▲ 8.30▲ 8.16▲ 7.86▲ 9.49▼
MA50 8.43▲ 8.05▲ 8.15▲ 8.23▲ 14.13▼
MA100 8.29▲ 8.13▲ 7.98▲ 9.65▼ 13.62▼
MA200 8.11▲ 7.94▲ 7.87▲ 13.20▼ 14.26▼
  5 mins 30 mins Hourly Daily Weekly
MACD -0.002▼ 0.018▲ 0.052▲ 0.098▲ 0.148▲
RSI 53.807▲ 66.364▲ 67.885▲ 57.633▲ 35.556▼
STOCH 72.329     93.894▲ 93.553▲ 52.092     31.347    
WILL %R -53.846     -12.963▲ -8.140▲ -19.014▲ -67.061    
CCI 34.375     108.213▲ 108.916▲ 113.237▲ -43.796    
Latest Filters Detected On CGEM
▲ RSI&VOL $CGEM RSI Cross Up and Volume Set Alert
RSI $CGEM RSI(14) Crossed Above 50 Set Alert
MA $CGEM Price Crossed Above MA(50) Set Alert
MA $CGEM Price Crossed Above MA(13) Set Alert
MA $CGEM Price Crossed Above MA(7) Set Alert
Cullinan Management Inc News
Cullinan Therapeutics launches Sjögren’s disease study
Tuesday, April 29, 2025 12:09 AM
CAMBRIDGE, Mass. - Cullinan Therapeutics, Inc. (NASDAQ: CGEM), a clinical-stage biotech company with a market capitalization of $454 million, announced today the initiation of a clinical study for ...
Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion ...
Wednesday, April 23, 2025 12:31 PM
CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies ...
Cullinan Therapeutics to Present Positive REZILIENT1 Study Results of Zipalertinib for NSCLC at 2025 ASCO Annual Meeting
Wednesday, April 23, 2025 07:21 AM
(Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that results from the REZILIENT1 study of zipalertinib in non-small cell ...
CGEM historical stock data
date open high low close volume
01/05/25 8.28 8.59 8.07 8.52 457,134
30/04/25 7.79 8.405 7.70 8.28 358,694
29/04/25 7.78 8.03 7.76 7.90 168,851
28/04/25 8.13 8.305 7.61 7.755 273,464
25/04/25 8.05 8.20 7.89 8.14 250,650
24/04/25 8.35 8.4108 7.98 8.14 218,450
23/04/25 8.60 8.79 8.37 8.38 377,921
22/04/25 8.20 8.42 7.86 8.37 1,121,549
21/04/25 7.82 8.39 7.82 8.10 342,088
17/04/25 7.42 7.989 7.38 7.89 694,947
Quote Details
52wk Low:6.85
52wk High:30.189
Vol:457.13K
Avg Vol(3m):6.6M
1Y Chng:-64.19%
1M Chng:-2.29%
Add to Watch List
More Information
Index US Composite
Market Cap. 457.66M